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151The impact of stent graft evolution on the results
of endovascular abdominal aortic aneurysm repair
Rami O. Tadros, MD, Peter L. Faries, MD, Sharif H. Ellozy, MD, Robert A. Lookstein, MD,
Ageliki G. Vouyouka, MD, Rachel Schrier, MD, Jamie Kim, MD, andMichael L. Marin, MD, New York, NY
Objective: There have been four eras in the development of endovascular aneurysm repair (EVAR): physician-made grafts,
early industry devices, intermediary commercial endografts, and modern stent grafts. This study analyzes differences in
outcomes between these four groups and the impact of device evolution and increased physician experience.
Methods: From 1992 to 2012, 1380 patients underwent elective EVAR. Fourteen different devices were used during this
time. The four generations were deﬁned as follows: era 1, all physician-made devices; era 2, June 1994 to June 2003; era
3, June 2003 to January 2008; and era 4, January 2008 to July 2012. Grafts used in each era were the following: era 1,
physician made; era 2, early industry, such as EVT, Talent, AneuRx, Excluder, Quantum LP, Vanguard, Ancure, and
Teramed; era 3, Talent, Endologix, Excluder, AAAdvantage, Zenith, and Aptus; and era 4, Zenith, Endurant, and
Excluder.
Results: Mean age was 75.2 years, and 84.5% were men. Adjunctive procedures decreased from era 1 to era 2 (P < .001)
but rose again in eras 3 and 4 (P < .001). Procedure times (P < .001), blood loss (P < .001), and length of stay (P < .001)
have decreased in eras 2, 3, and 4 compared with era 1. Major perioperative complications (era 1, 23%; era 2, 5.9%; era 3,
4.9%; and era 4, 4.7%; P < .001), abdominal aortic aneurysm-related perioperative mortality (era 1, 4.3%; era 2, 0.2%; era
3, 0.06%; and era 4, 0.5%; P < .001), and all-cause perioperative mortality (era 1, 7.7%; era 2, 1.9%; era 3, 1.5%; and era 4,
0.47%; P < .001) have also decreased in eras 2, 3, and 4 compared with era 1. Type I and type III endoleaks (P < .001) and
the need for reintervention (P < .001) have decreased. Freedom from aneurysm-related mortality has signiﬁcantly
improved.
Conclusions: EVAR has evolved during the last 20 years, resulting in an improvement in efﬁciency, outcomes, and
procedural success. The most signiﬁcant advance is seen in the transition from era 1 to the later eras. (J Vasc Surg
2014;59:1518-27.)More than two decades have passed since Parodi et al1
described the ﬁrst endovascular repair of an abdominal
aortic aneurysm (AAA). Nearly 2 years later, Marin
et al,2,3 instructed by Dr Parodi, performed the ﬁrst endo-
vascular repair of an AAA in the United States. First itera-
tion endografts for AAAs were used on a compassionate
basis.3 These patients were not candidates for an open
AAA repair because of severe surgical risk. Since that
time, endovascular aneurysm repair (EVAR) has become
the preferred approach and at present is the most common
procedure performed to correct AAA.4,5
When it was ﬁrst implemented, EVAR was used selec-
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8advanced, EVAR was used to treat more standard-risk pa-
tients. Physician-made devices continued to be used in this
standard-risk cohort until 2003. We hypothesized that de-
vice development and operator experience have resulted in
an overall improvement in EVAR outcomes. To demon-
strate improved outcomes over time, four generations of
EVAR were compared. Speciﬁcally, the results of treatment
with physician-made devices and three subsequent cohorts
of industry-made endografts were compared. The purpose
of these comparisons was to determine the impact of device
evolution and increased experience on outcomes.
METHODS
Study population. Between November 1992 and
May 2012, 1853 aortic endografts were implanted. Of
these procedures, 1380 patients underwent elective endo-
vascular repair of infrarenal AAA. For a homogeneous
patient population to be created for comparison, only pa-
tients undergoing an elective EVAR were included in this
analysis. Patients from two institutions were included: the
Monteﬁore Hospital, New York, and the Mount Sinai
Hospital, New York.
Of the original 1853 stent grafts, 473 patients were
excluded. These exclusions consisted of endografts placed
for pseudoaneurysms, para-anastomotic aneurysms, aor-
toenteric or aortoduodenal ﬁstulas, and penetrating ulcers.
In addition, patients undergoing endovascular repair of iso-
lated thoracic or iliac aneurysms, patients with aortic
Table I. Summary of Devices by Era
Device and manufacturer No. Dates used
Era 1: Physician made
Juan Parodi 9 11/92-01/95
Michael Marin 108 06/94-06/03
Era 2: Early industry
Endovascular Technologies (EVT) 5 06/94-05/96
Boston Scientiﬁc (Vanguard) 18 08/97-03/00
Guidant (Ancure) 9 05/00-03/01
Teramed (Ariba) 6 07/00-08/00
Cordis (Quantum LP) 31 04/02-04/03
Early Gore (Excluder) 20 05/98-06/03
Early Medtronic (Talent)a 402 04/98-03/11
Early AneuRx (AAAdvantage) 34 11/99-06/03
Era 3: Intermediary industry
Aptus Endovascular (Aptus)a 3 12/07-02/08
Powerlink (Endologix)a 3 12/06-05/12
Intermediary Gore (Excluder) 175 06/03-01/08
Late Medtronic (Talent)a 241 04/98-03/11
Late AneuRx (AAAdvantage)a 86 06/03-10/10
Early Cook (Zenith) 18 12/03-01/08
Era 4: Modern industry
Late Cook (Zenith) 9 01/08-02/12
Medtronic (Endurant) 69 09/08-07/12
Late Gore (Excluder) 134 01/08-07/12
Eras were deﬁned generally to categorize the various endografts as best as
possible by the time periods: era 1, all physician-made devices; era 2, June
1994 to June 2003; era 3, June 2003 to January 2008; era 4, January 2008
to July 2012.
EVT (Endovascular Technologies, Menlo Park, Calif); Vanguard (Boston
Scientiﬁc, Natick, Mass); Ancure (Guidant, Indianapolis, Ind); Ariba (Ter-
amed, Maple Grove, Minn); Quantum LP (Cordis, Waterloo, Belgium);
Excluder (Gore, Flagstaff, Ariz); Talent (Medtronic, Minneapolis, Minn);
AAAdvantage (AneuRx; Medtronic, Santa Rosa, Calif); Aptus (Aptus
Endovascular, Sunnyvale, Calif); Endologix (Powerlink, Irvine, Calif);
Zenith (Cook, Bloomington, Ind); and Endurant (Medtronic, Minneapolis,
Minn).
aThese devices were used outside of the date range deﬁned by the eras
because of case-by-case circumstances.
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tution for a secondary EVAR for endoleaks were excluded.
The physician-made device cohort excluded physician-
modiﬁed, industry-manufactured devices. Twenty-ﬁve pa-
tients were excluded because of lost or incomplete records.
Fourteen stent grafts were employed to treat the 1380
patients included in this study. These devices included 117
physician-made endografts and 1263 industry-manufactured
stent grafts (Table I). The study protocol was approved by
the Institutional Review Board.
Data collection. Demographics, preoperative charac-
teristics, and intraoperative procedure details were
collected from a prospectively maintained database that
has been sustained since the ﬁrst successful performance
of EVAR in North America. This database was supple-
mented with a retrospective review of medical records. Sur-
vival was determined with medical records and the Social
Security Death Index.
Medical high risk was assessed by the Glasgow Aneu-
rysm Score (GAS), which was calculated with the methods
described by Baas et al.6 Patients were considered high risk
when the GAS exceeded 76.5. Scores higher than 76.5
have been shown to increase the 30-day mortality rate
for EVAR to 1.9% and for open AAA repair to 7.8%.6
The overall numbers of comorbid conditions were calcu-
lated. Preoperative diagnostic angiography or computed
tomography angiography was performed to conﬁrm eligi-
bility for endovascular repair. Preoperative adjunctive pro-
cedures (eg, embolization, management of concomitant
occlusive disease) were also performed on an as-needed
basis.
The recorded intraoperative parameters included oper-
ative time, anesthesia time, estimated blood loss, number
of additional endovascular extensions, length of hospital
stay, minor and major complications, and mortality. The
use of additional extensions was deﬁned as use of an extra
cuff or limb in addition to the standard device conﬁgura-
tion. Complications, endoleak rates and types, aneurysm
growth, reinterventions, aneurysm-related death, and over-
all mortality were documented during the immediate post-
operative period (0-30 days after the procedure) and for
the entire duration of follow-up. Perioperative complica-
tions were deﬁned as postoperative complications occur-
ring within 30 days of EVAR. Complications were
classiﬁed as major or minor according to the severity and
extent of treatment required (Table II). These complica-
tions are consistent with the Society for Vascular Surgery
reporting standards.7
To evaluate the impact of physician experience and de-
vice evolution on procedural outcomes after EVAR, cases
were divided into four groups according to the type of
stent graft used and the time intervals during which those
devices were used (Table I). Era 1 (n ¼ 117) was deﬁned
as all physician-made devices. Era 2 (n ¼ 525) included
early industry devices, used between June 1994 and June
2003. Era 3 (n ¼ 526) comprised commercial endografts
implanted between June 2003 and January 2008 as well
as certain intermediary devices used after 2008 (Aptusand Endologix). Era 4 (n ¼ 212) was deﬁned as the
most recent stent grafts and consisted of the remaining de-
vices used between January 2008 and July 2012. The Med-
tronic AneuRx stent graft was used until October 2010,
and the Medtronic Talent endograft was used until March
2011. These devices were later superseded by the Med-
tronic Endurant. Therefore, the Talent and AneuRx were
not included in the fourth era but conﬁned to eras 2 and
3. The Cook Zenith and Gore Excluder were multigener-
ational and were used in several eras. Speciﬁcally, the
Excluder was used in eras 2, 3, and 4; the Zenith was
used in eras 3 and 4.
Follow-up. Follow-up was conducted per standard-of-
care practices. Patients were evaluated at 30 days, at
6 months, and annually thereafter. Follow-up for patients
enrolled in device trials was conducted in accordance with
investigational device exemption and postmarket protocols.
Patients unable to return to Mount Sinai but who agreed
to follow-up with a study investigator remotely (ie, by
mailing of imaging to the hospital) were included in this
analysis. Patients were considered lost to follow-up in the
Table II. Summary of minor and major complications
Complication type Major Minor
Deployment-related complications Access artery dissection or thrombosis
Arterial perforation or rupture
Conversion to open or procedure aborted
Failed deployment (no conversion)a
Implant-related complications AAA rupturea
Aortic dissection
Aortoenteric ﬁstula
Endograft migrationa
Pseudoaneurysm
Stent fracture
Lower extremity ischemia Occlusion, embolus, or thrombosis
requiring surgical intervention
Claudication or ischemia requiring medical
management only
Access site complication (infection,
hematoma, or lymphocele)
Access site complication requiring surgical
intervention or transfusiona
Access site complication requiring medical
management onlya
Cardiac complications Troponin leak or electrocardiographic
changes, requiring intervention
Medically managed, no troponin leak or
electrocardiographic changes
Pulmonary complications Respiratory failure, prolonged intubation
or tracheostomy
Atelectasis or reversible pulmonary issues
Renal complications Requiring dialysis, persistent creatinine
elevation
Contrast-induced nephropathy, transient
creatinine elevation
Other systemic complications Bowel ischemia
Coagulopathy
DVT
Postoperative bleeding with transfusion
Plaque emboli
Pulmonary embolism
Spinal cord ischemia
Stroke
Post-stent implant syndrome
Urinary tract infection
AAA, Abdominal aortic aneurysm; DVT, deep venous thrombosis.
aMost common complications (>1.5% of study population).
Table III. Patient characteristics and comorbidities
Characteristic No. (%) (N ¼ 1380)
Male gender 1166 (84.5)
Mean age 6 SD, years 75.2 6 8.24
Hypertension 1072 (82.1)
History of smoking 1048 (80.2)
Cardiac disease 962 (73.7)
Hypercholesterolemia 830 (63.6)
Pulmonary disease 406 (31.1)
Cerebrovascular disease 174 (17.9)
Diabetes 216 (16.5)
Renal disease 72 (5.5)
Number of comorbidities per patient
Era No. (N ¼ 1306) Mean 6 SD
1 108 3.7 6 1.23
2 488 3.58 6 1.29
3 500 3.58 6 1.29
4 210 4.01 6 1.27
SD, Standard deviation.
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known mortality. Aneurysm sac enlargement was deﬁned
as growth of $5 mm from the ﬁrst postoperative scan.
Endoleaks were deﬁned by the presence of ﬂow into the
aneurysm sac and outside of the lumen of the endovascular
graft on an imaging study. Computed tomography angio-
graphy was normally performed at the time of follow-up or
at more frequent intervals when deemed necessary. Radi-
ography was also used to evaluate for stent fractures.
Magnetic resonance angiography, duplex ultrasound, and
angiography were used as needed to further evaluate
aneurysm sac enlargement, endoleaks, migration, and
patency.
Surgical technique. The majority of procedures were
performed with spinal or epidural anesthesia and moni-
tored anesthesia care. General anesthesia was used in select
cases. The procedures were performed in the operating
room with use of a mobile ﬂuoroscopic unit. Most EVARs
were performed with bilateral femoral artery exposures
through oblique incisions. Iliac conduits and iliac exposures
for device delivery were used on a case-by-case basis.
Arterial repair was performed primarily in most instances.
Patch repair with or without endarterectomy was used
when needed to maintain limb perfusion. Within the study
period described, two percutaneous EVARs were per-
formed during era 4. Attending vascular surgeons per-
formed or supervised all portions of the EVARs.Statistical analysis. All data were analyzed in SPSS
Statistics 20 (IBM, Armonk, NY). Comparisons between
the four device generations were analyzed for signiﬁcance
by an analysis of variance for continuous variables. When
Table IV. Preoperative adjunctive procedures
Preoperative adjunctive
procedures by type No. (N ¼ 493)
% total patients
(N ¼ 1380)
Hypogastric embolization 293 21.23
IMA embolization 155 11.23
CIA stent/angioplasty 12 0.87
Renal intervention
(angioplasty, stent)
65 4.71
Othera 16 1.16
Preoperative adjunctive
breakdown by era No. (N ¼ 493)
% total
patients in era
Era 1 (n ¼ 117) 59 50.4
Era 2 (n ¼ 525) 119 22.8
Era 3 (n ¼ 526) 226 43.0
Era 4 (n ¼ 212) 89 42.0
Hypogastric embolization No. (N ¼ 293)
% total
patients in era
Era 1 (n ¼ 117) 56 47.9
Era 2 (n ¼ 525) 85 16.2
Era 3 (n ¼ 526) 103 19.6
Era 4 (n ¼ 212) 49 23.1
IMA embolization No. (N ¼ 155)
% total
patients in era
Era 1 (n ¼ 117) 0 0
Era 2 (n ¼ 525) 13 2.5
Era 3 (n ¼ 526) 103 19.6
Era 4 (n ¼ 212) 39 18.4
CIA, Common iliac artery; IMA, inferior mesenteric artery.
aOther: Deployment of Trapease ﬁlter in inferior vena cava, femoropopliteal
bypass, aborted, lumbar artery embolization, external iliacehypogastric
bypass, iliofemoral bypass, external iliacerenal artery bypass, splenic artery
embolization, superior mesenteric artery angioplasty and stenting.
Table V. Intraoperative parameters
Procedure time No. Mean 6 SD, hours:minutes
All eras 1192 3:43 6 1:25
Era 1 97 4:45 6 1:36
Era 2 438 3.35 6 1:23
Era 3 460 3:45 6 1:22
Era 4 197 3:23 6 1:13
Anesthesia type No. %
Spinal or epidural 1222 88.5
General 95 6.9
Monitored anesthesia care 30 2.2
Unknown 33 2.4
Estimated blood loss No. Mean 6 SD, mL
All eras 1056 340.23 6 379.53
Era 1 73 566.58 6 798.70
Era 2 356 359.83 6 311.44
Era 3 448 327.09 6 361.11
Era 4 179 241.82 6 206.93
Patients requiring a transfusion No. (%) (N ¼ 1380)
All eras 179 (13)
Era 1 34 (29.1)
Era 2 49 (9.3)
Era 3 70 (13.3)
Era 4 27 (12.7)
Transfusion volumea No. Mean 6 SD, mL
All eras 179 574.33 6 461.92
Era 1 34 727.94 6 146.77
Era 2 49 545.92 6 45.34
Era 3 70 518.64 6 36.53
Era 4 27 555.56 6 50.52
SD, Standard deviation.
aNot signiﬁcant (P ¼ .17).
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correction was applied. A c2 test with a Bonferroni adjust-
ment was used for discrete variables. Kaplan-Meier analysis
with a log-rank test was used to assess survival, AAA-related
mortality, time to endoleak, and time to EVAR-related
reintervention. A Scheffe correction was used when mul-
tiple comparisons were made by Kaplan-Meier analysis.RESULTS
Patient characteristics and preoperative measures.
The median age was 75.2 6 8.2 years, and 1166 patients
(84.5%) were male; 1289 (98.7%) of the population
exhibited at least one severe comorbid condition, with an
average number of comorbidities being 3.7 6 1.3 per pa-
tient (Table III). Concomitant common iliac or thoracic
aortic aneurysms were observed in 492 patients (37.7%).
The mean GAS for the entire cohort was 81.66 10.4, with
930 patients (71.2%) being considered high risk with scores
above 76.5. The mean GAS was 82.7 in era 1, 81.3 in era
2, 81.6 in era 3, and 81.2 in era 4. There was no signiﬁcant
difference in scores between eras. There was a signiﬁcantincrease in the number of comorbidities reported in era 4
(era 1, 3.7; era 2, 3.6; era 3, 3.6; and era 4, 4.0; P < .001).
Preoperative adjunctive procedures were performed on
493 patients (35.72%), including hypogastric artery and
inferior mesenteric artery embolization and treatment of
concomitant vascular occlusive disease (Table IV). The
number of adjunctive procedures performed decreased
from 50.4% to 22.8% from era 1 to era 2 (P < .001).
The use of physician-made devices in era 1 required hypo-
gastric embolization in 47.9% of cases. Hypogastric embo-
lization was implemented in 16.2% of era 2, 19.6% of era 3,
and 23.1% of era 4 patients. The number of adjunctive pro-
cedures has increased from era 2 to era 3 (P < .001) and
from era 2 to era 4 (P < .001). These ﬁndings are due
to an increased use of inferior mesenteric artery emboliza-
tion in era 3 and era 4. The numbers of adjunctive proce-
dures performed were similar between eras 1, 3, and 4.
Intraoperative parameters. Mean procedure times
were signiﬁcantly greater in era 1 compared with the later
eras (Table V; P < .001). Estimated blood loss decreased
Table VI. Intraoperative complication rates
Intraoperative complication type No. % total patients
None 1310 94.9
Any 71 5.1
AAA rupture 1 0.1
Aortic dissection 1 0.1
Access artery dissection or thrombosis 8 0.6
Arterial perforation or rupture 8 0.6
Cardiac 4 0.3
Pulmonary 3 0.2
Deployment-related complications 22 1.6
Endograft migration 2 0.1
Bowel ischemia 1 0.1
Limb occlusion, thrombosis, or embolism 7 0.5
Procedure aborted or converted to open 14 1.0
Era Intraoperative complications, No. (%)
1 (n ¼ 117) 20 (17.1)
2 (n ¼ 525) 28 (5.3)
3 (n ¼ 526) 16 (3.0)
4 (n ¼ 212) 6 (2.8)
AAA, Abdominal aortic aneurysm.
Table VII. Discharge data and length of stay
Discharged on
postoperative day 1 No. (N ¼ 1173) % overall patients
Era 1 5 4.3
Era 2 318 60.6
Era 3 424 80.6
Era 4 186 87.7
Length of stay No. (N ¼ 1351) Mean 6 SD
Era 1 105 7.19 6 9.49
Era 2 508 2.35 6 3.76
Era 3 526 2.03 6 3.58
Era 4 212 1.72 6 2.98
SD, Standard deviation.
Table VIII. Endoleak and reintervention rates
Era No. (%)
Type I
1 11 (11.0)
2 75 (15.5)
3 47 (9.3)
4 6 (3.0)
Type II
1 16 (16.0)
2 114 (23.5)
3 147 (29.2)
4 58 (29.3)
Type I or III
1 11 (11.0)
2 83 (17.1)
3 49 (9.7)
4 6 (3.0)
Reintervention rate
1 39 (33.3)
2 143 (27.25)
3 97 (18.4)
4 21 (9.9)
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were observed in estimated blood loss between era 2 and
era 3, but era 4 had a lower estimated blood loss compared
with eras 2 and 3 (P < .001). Intraoperative transfusions
were administered to 179 patients (13.0%), with a mean
transfusion volume of 574.36 461.9 mL. More patients in
era 1 received a blood transfusion compared with the other
eras (P < .001). The mean transfusion volumes were
similar between the eras. General anesthesia was employed
in only 95 cases (6.9%); the majority of procedures (1285;
93.1%) were performed under spinal anesthesia, epidural
anesthesia, or monitored anesthesia care.
At least one endograft extension was placed intraoper-
atively in 549 patients (39.8%), with a signiﬁcant increase in
the number of extensions used in comparison of eras 1 and
2 and eras 2 and 3 or 4 (P < .001). A similar number of
extensions were used in eras 3 and 4. Major intraoperative
complications were experienced by 71 patients (5.1%)
overall and signiﬁcantly declined in eras 2, 3, and 4
compared with era 1 (P < .001). Intraoperative complica-
tions were similar between eras 2, 3, and 4 (Table VI).
Most patients (893; 64.7%) were discharged on the ﬁrst
postoperative day, with a mean length of stay of 2.5 6 4.5
days (Table VII). When the four groups were compared,
the number of patients discharged on postoperative day 1
increased from era 1 to eras 2, 3, and 4 (P< .001) and further
increased from era 2 to eras 3 and 4 (P< .001). The numbers
of patients discharged on postoperative day 1 were similar be-
tween eras 3 and 4. Length of stay decreased signiﬁcantly in
eras 2, 3, and 4 compared with era 1 (P < .001). Length of
stay was similar between eras 2, 3, and 4.
Postoperative outcomes. Mean follow-up time was
30.9 6 33.3 months. Aneurysm growth was observed in
170 patients (12.3%), and average time to aneurysm
expansion was 56.8 6 36.0 months. During follow-up,139 patients (10.1%) experienced a type I endoleak, and
12 patients (0.9%) experienced a type III endoleak. Era 4
demonstrated fewer type I endoleaks compared with eras 1,
2, and 3 (P < .001); era 3 demonstrated fewer type I
endoleaks compared with eras 1 and 2 (P < .001); how-
ever, eras 1 and 2 were similar (Table VIII). This ﬁnding,
however, was not signiﬁcant when length of follow-up was
accounted for by a Kaplan-Meier analysis (Fig 1). Type II
endoleaks were observed in 335 patients (24.3%), 75
(22.4%) of whom required reintervention for the endoleak.
Signiﬁcantly more type II endoleaks were observed in eras
3 and 4 compared with era 1 (P < .01; Fig 2). Type III
endoleaks also decreased over time, with the greatest rate
(1.9%) seen in era 3 and the lowest rate (0.0%) in era 4
(P < .01). AAA expansion, in the absence of endoleak, was
observed in 36 patients (2.6%). Of the total population
studied, reintervention was required in 263 patients
(19.1%), and mean time to reintervention was 25.4 6
28.6 months. Overall, the freedom from reintervention at
3 years was 83.5% (Fig 3). The reintervention rates were
Fig 1. A Kaplan-Meier analysis of type I endoleaks between four eras compared by a log-rank test with Scheffe
correction for multiple comparisons. Total at risk, N ¼ 1378; era 1, n ¼ 116; era 2, n ¼ 524; era 3, n ¼ 526; era 4,
n ¼ 212; overall, P ¼ .48. The standard error did not exceed 10%.
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from era 1 to eras 3 and 4 (P < .001), from era 2 to eras 3
and 4 (P < .001), and from era 3 to era 4 (P ¼ .004). The
freedom from reintervention also signiﬁcantly improved
over time in comparison of the four eras by a Kaplan-Meier
analysis because of differences observed between eras 1 and
3 or 4 (Table VIII; Fig 4).
Of the entire cohort, major perioperative complica-
tions occurred in 94 patients (6.8%), with perioperative
mortality rate of 2.0%. Major perioperative complication
rates were signiﬁcantly higher in era 1 compared with
the other eras (P < .001; Table IX). Further, periopera-
tive mortality rates were also signiﬁcantly lower in eras
2, 3, and 4 compared with era 1 (P < .001), decreasing
from 7.7% of patients in era 1 to 0.47% of patients in
the ﬁnal era. Minor perioperative complications occurred
in 62 patients (4.5%).
The overall freedom from aneurysm-related mortality
was 97.5% at 3 years. Freedom from aneurysm-related
mortality signiﬁcantly improved over time because of dif-
ferences observed between eras 1 and 4 (Fig 5). The
mean survival for all-cause mortality was 6.15 years by
Kaplan-Meier analysis, with the predominant cause of
death being cardiac related.
DISCUSSION
EVAR has clearly evolved since Juan Parodi’s ﬁrst
description.1 To demonstrate this evolution, we divided
our experience with EVAR into four eras for comparison.
The ﬁrst era consists of physician-made devices. The remain-
ing three groups are composed of three iterations of
industry-made endografts. Using this fund of information,we demonstrate an evolution of this technology and in-
creased operator experience and proﬁciency during the
past 2 decades. This growth and development have resulted
in improvements in procedural outcomes. Each new gener-
ation is the product of innovation and targeted efforts to
reduce complications and the need for reintervention.
Our data support the notion that physicians are more facile
with EVAR and that stent graft technology has improved
during the last 20 years. Although the concept of aneurysm
exclusion has persisted during the past 2 decades, techno-
logic advances have improved the capacity of stent grafts
to treat aortic aneurysms.
Physician-made devices were available in two conﬁgu-
rations: an aorto-aortic graft and an aortouni-iliac graft
that was accompanied by femoral-to-femoral bypass.
Soon after these early devices were implemented, several
early observations were made. The aorto-aortic grafts had
a high failure rate that necessitated reintervention or
open surgical conversion. These drawbacks caused this
conﬁguration to lose favor, and it was quickly retired.8,9
The physician-made aortouni-iliac device was more reliable
and applicable to many aneurysm types. Despite the avail-
ability of early manufactured devices, the aortouni-iliac
design stayed in use at our institution until June 2003
(Table I). The need for a femoral-to-femoral bypass in
era 1 may account for some of the observations we report.
Speciﬁcally, the increased rate of intraoperative complica-
tions, need for blood transfusions, and longer length of
stay may be the result of this additional procedure.
Several developments were put into practice during the
inception of EVAR. The most notable advancement is the
development and implementation of a modular bifurcated
Fig 2. A Kaplan-Meier analysis of type II endoleaks between four eras compared by a log-rank test with Scheffe
correction for multiple comparisons. Total at risk, N ¼ 1378; era 1; n ¼ 116; era 2, n ¼ 524; era 3, n ¼ 526; era 4,
n ¼ 212; overall, P < .0001. No difference was observed between era 1 and era 2. Statistically signiﬁcant differences
were observed between eras 1 and 3 or 4. Statistically signiﬁcant differences were observed between eras 2 and 3 or 4.
For era 1, the standard error exceeded 10% at 7.5 years and 10 years, where the standard error is 15%.
Fig 3. Overall, freedom from reintervention at 3 years ¼ 83.5%. Total at risk, N ¼ 1374. No reintervention data
available on four patients.
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balloon-expandable bare metal stent for transrenal stent
graft ﬁxation. This practice was found to reduce proximal
endoleaks.10 This technology laid the foundation for
many of the suprarenal ﬁxation stents found on many de-
vices today.In the current study, industry-made devices were ﬁrst
used in 1994 (Table I). With the advent of commercially
produced devices, many new observations were made
that helped characterize the various mechanisms of stent
graft failure.11 These ﬁndings as well as the discoveries of
others helped foster an innovative environment aimed at
Fig 4. A Kaplan-Meier analysis of reinterventions between four eras compared by a log-rank test with Scheffe
correction for multiple comparisons. Total at risk, N ¼ 1374; era 1, n ¼ 115; era 2, n ¼ 522; era 3, n ¼ 525; era 4,
n ¼ 212; P ¼ .0009. Statistically signiﬁcant differences were observed only between eras 1 and 3 or 4. The standard
error did not exceed 10%.
Table IX. Perioperative complication and mortality rates
Era No. (%)
Major 30-day complications
1 27 (23.1)
2 31 (5.9)
3 26 (4.9)
4 10 (4.7)
All-cause 30-day mortality
1 9 (7.7)
2 10 (1.90)
3 8 (1.52)
4 1 (0.47)
AAA-related 30-day mortality
1 5 (4.3)
2 1 (0.2)
3 3 (0.6)
4 1 (0.5)
AAA, Abdominal aortic aneurysm.
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 6 Tadros et al 1525device improvement. New stent grafts were developed with
the goal of reducing failure rates, improving outcomes, and
increasing device applicability. Improved fabrics, better
scaffolding designs and materials, lower proﬁle delivery sys-
tems, precise deployment mechanisms, enhanced ﬁxation,
greater conformability, and diverse modular components
were developed and applied to newer generation
endografts.
The ﬁrst patients were treated on a compassionate ba-
sis and were known to be more ill than patients treated
later. Although physician-made devices were used to treat
these early patients, this technology remained in use well
beyond this early phase until June 2003. To more accu-
rately evaluate the impact of device design rather than
patient-related factors, we clustered all physician-made
devices into a single cohort. This grouping allowed a
more uniform cohort for comparison between the eras.
The remaining three eras were divided mainly by the
time frame in which speciﬁc devices were used. To
compare the risk of morbidity and mortality between
the groups due to age and medical comorbidities, we
calculated GAS. Scores were comparable between the
eras; 71.2% were considered high risk.
Some of the observed improvements are due to
increased operator experience. We found that procedure
times, blood loss, and the number of intraoperative compli-
cations declined. The decreased rate of intraoperative com-
plications may also be due to lower proﬁle devices,
improved stent graft ﬂexibility, hydrophilic delivery sys-
tems, and other device-related factors.Early endografts were manufactured and customized
on the basis of preprocedural measurements. This process
delayed treatment until the stent graft was produced and
available. Diverse modular device components, greater
conformability, and lower proﬁle delivery systems have
allowed a broader application of this technology to a wider
array of aneurysms with an off-the-shelf endograft. The
multitude of conﬁgurations achieved with modular compo-
nents allows treatment of patients who may have been
excluded previously. Further, the time from diagnosis to
treatment has decreased. As a consequence of these
Fig 5. A Kaplan-Meier analysis of freedom from aneurysm-related deaths between four eras compared by a log-rank
test with Scheffe correction for multiple comparisons. Total at risk, N ¼ 1378; era 1, n ¼ 116; era 2, n ¼ 524; era 3,
n ¼ 526; era 4, n ¼ 212; P ¼ .0005. Statistically signiﬁcant differences were observed only between eras 1 and 4. The
standard error did not exceed 10%.
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sions being used during the later eras.
We found that perioperative major complications and
type I and type III endoleaks have decreased in the later
eras compared with era 1. More type II endoleaks are being
detected in the modern eras; this may be the result of the
enhanced imaging available during the last 10 years. Fewer
reinterventions are being performed after EVAR, and the
rate of reintervention after EVAR continues to decline.
As a cumulative consequence of these improvements, the
mortality rates after EVAR continue to improve, and the
freedom from aneurysm-related death has increased to an
outstanding 99.5% at 3 years.
In looking at the three randomized clinical trials
comparing EVAR with open aneurysm repair (EVAR 1,
DREAM, and OVER), we see progressively improved out-
comes.12-15 These observations become clear when these
studies are broken down by the years of enrollment and de-
vices used during those times.
The EVAR 1 trial enrolled patients between September
1999 and December 2003.16 The majority (99%) of the
stent grafts used were commercially available. Most of the
devices were either Cook Zenith or Medtronic Talent,
with fewer Gore Excluder, Medtronic AneuRx, and Cordis.
In this study, the 30-day mortality rate was 2.1%, with a
41% complication rate and 20% reintervention rate at
4 years. The Dutch Randomized Endovascular Aneurysm
Management (DREAM) trial enrolled patients from
November 2000 to December 2003.13 The predominant
devices were the Cook Zenith, Gore Excluder, and Med-
tronic Talent. The 30-day mortality in this trial was 1.2%,with an overall moderate to severe complication occurring
in 17% of the total population. The Open vs Endovascular
Repair (OVER) trial enrolled patients between October
2002 and October 2007. This study is unique in that
2-year and 9-year follow-up data have been published.
The majority of the devices were the Cook Zenith, Gore
Excluder, and Medtronic AneuRx. This study boasts the
best 30-day mortality rate, measuring 0.5%, with 22.1%
of patients requiring a secondary procedure at 9 years.
Although our study is not randomized and is not a com-
parison with open aneurysm repair, we show a similar step-
wise improvement in 30-day mortality rates. The mortality
rates have decreased from 7.7% in era 1 to 1.9% in era 2
and subsequently declined further to 0.47% in the ﬁnal
era. Importantly, we also demonstrate improvements in peri-
operative and late complications and a decreased need for
reintervention. Our data demonstrate that EVAR outcomes
have progressively improved during the last 2 decades.
Several limitations to our study exist. First, this is not a
randomized study. The majority of the data were collected
prospectively and analyzed retrospectively. There are selec-
tion biases. As more providers began to use EVAR, the
referral pattern shifted. The complexity of the aneurysms
referred to our center has increased. The duration of
follow-up or the patients lost to follow-up can have an
impact on our results, but Kaplan-Meier analyses were
used to account for this possibility. Further, the impact of
aneurysm morphology and treatment in and out of the in-
structions for use cannot be assessed at the present time.
Efforts are being made to collect this anatomic information
for futures studies.
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Operator experience and familiarity with EVAR have
improved during the past 20 years. These advances have
resulted in decreased procedure times and blood loss and
improved intraprocedural and perioperative complication
rates. The incidence of type I and type III endoleaks has
decreased, and the need for reintervention has declined.
Aneurysm-related mortality rates after EVAR are lower
now than in the past, and these results continue to improve.
The most obvious innovation accounting for these im-
provements is the transition from use of physician-made de-
vices to the use of industry-made devices.
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